Trials / Completed
CompletedNCT04508426
Single-dose AME Study With [14C]AR882 in Healthy Male Subjects
A Phase 1, Absorption, Metabolism, and Excretion Study of [14C]AR882 Orally Administered to Healthy Adult Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Arthrosi Therapeutics · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is an open-label, single-dose, absorption, metabolism, excretion, and mass balance study following a single dose of \[14C\]AR882 in healthy adult male subjects. Whole blood, plasma, urine, and fecal samples will be analyzed for at least 144 hours following the single dose of AR882 to measure total radioactivity and plasma drug concentrations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | [14C]AR882 | Single dose of \[14C\]AR882 |
Timeline
- Start date
- 2020-07-16
- Primary completion
- 2020-08-12
- Completion
- 2020-08-12
- First posted
- 2020-08-11
- Last updated
- 2020-11-16
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04508426. Inclusion in this directory is not an endorsement.